Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dial eyes aquisitions

This article was originally published in The Tan Sheet

Executive Summary

Firm looking to expand by purchasing new brand for its personal cleaning or household products divisions, CEO Herb Baum states at Banc of America securities Health Conference in San Francisco Sept. 16. Any acquisition "has to have an 18% or higher operating margin" to fit in company's current distribution system, exec notes, adding "we're good at liquid in a bottle." Baum also says international expansion is on hold after prior management team's ill-fated efforts in Argentina (1"The Tan Sheet," February 10, 2003, p. 10). "We're going to stay close to home...[as] there is a lot of growth left in North America," he asserts. Company is "comfortable" with third quarter and full-year guidance of $0.34 and $1.33 earning per share, respectively...

You may also be interested in...

Sales & Earnings In Brief

Bausch & Lomb: Worldwide lens care sales rose 8% to $121 mil. in Q4, led by ReNu products' double-digit gains in the Americas and Asia, according to Jan. 30 1company announcement. For the year, lens care revenues advanced 12% to $465.5 mil. Positive lens care performance, along with similar strong gains in contact lens and pharmaceuticals sales, helped power 9% overall sales increase to $1.81 bil. in 2002 versus the previous year, firm reports; full year net earnings rose to $72.5 mil. in 2002 from $21.2 mil. a year ago. B&L expects "low single-digit growth in" lens care sales in 2003. Additionally, Chairman & CEO Ronald Zarrella will oversee firm's Americas region commercial business until a successor is named for B&L exec Mark Sieczkarek, who left Jan. 31 "to pursue career opportunities elsewhere"...

US FDA Addresses PFAS In Cosmetics, Aiming To Close Data Gaps

Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.

Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions

Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts